Aptose Biosciences Inc. (NASDAQ:APTO) fell 5.9% during mid-day trading on Monday . The company traded as low as $2.36 and last traded at $2.38, with a volume of 76,290 shares changing hands. The stock had previously closed at $2.53.

A number of research firms have recently issued reports on APTO. Royal Bank Of Canada restated an “outperform” rating and issued a $23.00 price target on shares of Aptose Biosciences in a research report on Monday, June 13th. Canaccord Genuity restated a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a research report on Thursday, June 9th. Zacks Investment Research lowered Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 11th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Aptose Biosciences in a report on Thursday, June 9th. Finally, Roth Capital upgraded Aptose Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $4.00 to $8.00 in a report on Monday, June 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $12.30.

The company’s 50-day moving average price is $2.58 and its 200-day moving average price is $2.63. The firm’s market cap is $29.68 million.

Aptose Biosciences Inc (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.